Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) Chairman P Roy Vagelos sold 11,972 shares of the company’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $340.11, for a total value of $4,071,796.92. Following the completion of the transaction, the chairman now directly owns 256,568 shares in the company, valued at approximately $87,261,342. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

REGN has been the subject of a number of recent research reports. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Regeneron Pharmaceuticals presently has an average rating of “Buy” and an average target price of $345.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.14% during mid-day trading on Monday, hitting $338.81. 508,355 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a one year low of $227.64 and a one year high of $352.49. The stock’s 50-day moving average is $307. and its 200-day moving average is $306.5. The company has a market cap of $34.013 billion and a price-to-earnings ratio of 96.28.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.47 earnings per share for the quarter, beating the analysts’ consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter last year, the company posted $1.73 earnings per share. Regeneron Pharmaceuticals’s revenue was up 45.4% compared to the same quarter last year. Analysts expect that Regeneron Pharmaceuticals will post $10.08 EPS for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.